

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2010; month=7; day=20; hr=9; min=9; sec=38; ms=742; ]

=====

\*\*\*\*\*

Reviewer Comments:

<210> 42

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln

1 5

The above <223> response contains an error: "Xaa at position 3" is shown twice; the third "Xaa" is at position 4.

Minor errors below:

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(4)  
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 =  
an y amino acid residue, Xaa at position 4 = any amino acid  
residue

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa  
1 5

The above <223> response explaining Xaa contains a misspelling: please  
replace "resdue" with "residue".

<210> 40  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr  
1 5

In the last <223> response (explaining the "Xaa" at location 4: please  
correct it to read "Xaa at position 4 = Thr or Ser"

\*\*\*\*\*

Application No: 10559758 Version No: 3.0

**Input Set:****Output Set:**

**Started:** 2010-07-19 17:39:10.333  
**Finished:** 2010-07-19 17:39:13.068  
**Elapsed:** 0 hr(s) 0 min(s) 2 sec(s) 735 ms  
**Total Warnings:** 62  
**Total Errors:** 0  
**No. of SeqIDs Defined:** 62  
**Actual SeqID Count:** 62

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

**Input Set:**

**Output Set:**

**Started:** 2010-07-19 17:39:10.333  
**Finished:** 2010-07-19 17:39:13.068  
**Elapsed:** 0 hr(s) 0 min(s) 2 sec(s) 735 ms  
**Total Warnings:** 62  
**Total Errors:** 0  
**No. of SeqIDs Defined:** 62  
**Actual SeqID Count:** 62

**Error code**

**Error Description**

This error has occurred more than 20 times, will not be displayed

# SEQUENCE LISTING

<110> Hart, Stephen Lewis  
 Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> 10559758

<141> 2010-07-19

<150> GB 03 13132.3

<151> 2003-06-06

<150> PCT/GB2004/002421

<151> 2004-06-07

<160> 62

<170> PatentIn version 3.5

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a  
 ny amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr  
 1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser

1

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid, Xaa at position 3 = any amino acid having an amide side chain, Xaa at position 4 = any amino acid

<400> 3

Gln Xaa Xaa Xaa Gln

1 5

<210> 4

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue having an aliphatic side chain

<400> 4

Ser Xaa Ser

1

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr  
1 5

<210> 6  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 6

Pro Ala Leu Lys Thr  
1 5

<210> 7  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr  
1 5



<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells  
  
<400> 8

Pro Ser Asn Ser Thr  
1 5

<210> 9  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells  
  
<400> 9

Pro Pro Asn Thr Thr  
1 5

<210> 10  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(4)  
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 =  
an y amino acid residue, Xaa at position 4 = any amino acid  
residue

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 11  
<211> 6

<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa  
1 5

<210> 12  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (6)..(6)  
<223> Xaa at position 6 = any amino acid residue

<400> 12

Pro Xaa Asn Xaa Thr Xaa  
1 5

<210> 13  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa at position 1 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (3)..(5)  
<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

<400> 13

Xaa Pro Xaa Xaa Xaa Thr  
1 5

<210> 14  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa at position 1 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (3)..(5)  
<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = any amino acid residue, Xaa at position 5 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 15  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 15

Ala Pro Ser Asn Ser Thr Ala  
1 5

<210> 16  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 16

Ser Pro Ala Leu Lys Thr Val  
1 5

<210> 17  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 17

Ser Thr Pro Pro Asn Thr Thr  
1 5

<210> 18  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 18

Pro Ser Asn Ser  
1

<210> 19  
<211> 4  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells  
  
<400> 19

Pro Ser Leu Ser  
1

<210> 20  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa at position 1 = Ala or Lys

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser  
1 5

<210> 21  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells  
  
<400> 21

Ala Pro Ser Asn Ser  
1 5

<210> 22  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 22

Leu Pro Ser Leu Ser  
1 5

<210> 23  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 23

Met Leu Pro Ser Leu Ser  
1 5

<210> 24  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 24

Pro Met Leu Pro Ser Leu Ser  
1 5

<210> 25  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 25

Ser Gln Lys Asn Pro Gln Met  
1 5

<210> 26  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 26

Phe Gln Ser Gln Tyr Gln Lys  
1 5

<210> 27  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 27

Met Ala Ser Ile Ser Met Lys  
1 5

<210> 28  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 28

Asp Trp Trp His Thr Ser Ala  
1 5

<210> 29  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<400> 29

Ser His Val Lys Leu Asn Ser  
1 5

<210> 30  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 30

Gln Leu Leu Thr Gly Ala Ser  
1 5

<210> 31

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 31

Thr Ala Arg Asp Tyr Arg Leu  
1 5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 32

Phe Pro Arg Ala Pro His His  
1 5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 33

Ser Glu Trp Leu Ser Ala Leu  
1 5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells



<400> 34

Ile Gly Gly Ile Arg Arg His  
1 5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 35

Tyr Thr Met Glu Phe Asn Arg  
1 5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 36

Pro Ala Ala Tyr Lys Ala His  
1 5

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC\_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a  
ny amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa  
1 5

<210> 38  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue,

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr  
1 5

<210> 39  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(4)  
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr  
1 5

<210> 40  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa at position 2 = any amino acid residue

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr  
1 5

<210> 41  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa at position 1 = Ala or Leu

<220>  
<221> MISC\_FEATURE  
<222> (4)..(4)  
<223> Xaa at position 4 = any amino acid residue

<400> 41

Xaa Pro Ser Xaa Ser  
1 5

<210> 42  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide binding to dendritic cells

<220>  
<221> MISC\_FEATURE  
<222> (2)..(4)  
<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A  
sn or Gln, Xaa at position 3 = any amino acid residue



Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly  
20 25

<210> 46  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide derivative of the invention

<400> 46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly  
20 25

<210> 47  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide derivative of the invention

<400> 47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly  
20 25

<210> 48  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide derivative of the invention

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly

20

25

<210> 49

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly  
20 25

<210> 50

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly  
20 25

<210> 51

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 51

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Arg Arg Glu Glu Trp Ala Cys Gly  
20 25

<210> 52  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide derivative of the invention

<400> 52

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gln  
20 25

<210> 53  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> integrin-binding peptide

<400> 53

Arg Arg Glu Thr Glu Trp Ala  
1 5

<210> 54  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic nucleic acid binding domain

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15

<210> 55  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> hydrophobic spacer sequence

<220>  
<221> MISC\_FEATURE

<222> (1)..(1)  
<223> x = epsilon-amino hexanoic acid residue

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> x = epsilon-amino hexanoic acid residue

<400> 55

Xaa Ser Xaa Gly Ala  
1 5

<210> 56  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 56  
ccctcattag cgtaacg

17

<210> 57  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> control peptide

<400> 57

Ala Thr Arg Trp Ala Arg Glu  
1 5

<210> 58  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide encoding peptide ligand

<400> 58  
ccggaagcca cgtcaagctg aacg

24

<210> 59  
<211> 27  
<212> DNA  
<213> Artificial Sequence



<220>  
<223> complementary oligonucleotide encoding SEQ ID NO:29

<400> 59  
ccggcgctgt tcagcttcac gtggctt

27

<210> 60  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Peptide ligand

<400> 60

Ala Pro Thr